<?xml version="1.0" encoding="UTF-8"?>
<p>Andosan
 <sup>TM</sup> has also shown anti-inflammatory effects in vivo in human subjects. In two different trials with healthy individuals, the ingestion of this drug provoked a reduction in proinflammatory cytokines, and an increased shedding expression of the adhesion molecule CD62L (L-selectin) and decreased intracellular reactive oxygen species (iROS), both in monocytes and granulocytes [
 <xref rid="B70-ijms-22-00634" ref-type="bibr">70</xref>]. An improvement of quality of life was obtained by administering 60 mL of Andosan
 <sup>TM</sup> for 21 days to patients with ulcerative colitis or Crohnâ€™s disease, as well as a reduction in plasma levels of IL-5 and IL-2, respectively [
 <xref rid="B58-ijms-22-00634" ref-type="bibr">58</xref>]. However, this study also found additional effects (improvement of total fatigue and/or lower cytokine levels) that have not yet been fully clarified.
</p>
